Title: Full Text of HB2584
Official Title: 
Number of Sections: 1
Source: versions - Engrossed
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly HB2584 EngrossedLRB104 08321 BAB 18372 b1    AN ACT concerning regulation. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Insurance Code is amended by 5changing Section 356z.60 as follows: 6    (215 ILCS 5/356z.60)7    Sec. 356z.60. Coverage for abortifacients, hormonal 8therapy, and human immunodeficiency virus pre-exposure 9prophylaxis and post-exposure prophylaxis.10    (a) As used in this Section:11    "Abortifacients" means any medication administered to 12terminate a pregnancy as prescribed or ordered by a health 13care professional.14    "Health care professional" means a physician licensed to 15practice medicine in all of its branches, licensed advanced 16practice registered nurse, or physician assistant.17    "Hormonal therapy medication" means hormonal treatment 18administered to treat gender dysphoria.19    "Therapeutic equivalent version" means drugs, devices, or 20products that can be expected to have the same clinical effect 21and safety profile when administered to patients under the 22conditions specified in the labeling and that satisfy the 23following general criteria:  HB2584 Engrossed- 2 -LRB104 08321 BAB 18372 b1        (1) it is approved as safe and effective;2        (2) it is a pharmaceutical equivalent in that it:3            (A) contains identical amounts of the same active 4        drug ingredient in the same dosage form and route of 5        administration; and6            (B) meets compendial or other applicable standards 7        of strength, quality, purity, and identity;8        (3) it is bioequivalent in that:9            (A) it does not present a known or potential 10        bioequivalence problem and it meets an acceptable in 11        vitro standard; or12            (B) if it does present such a known or potential 13        problem, it is shown to meet an appropriate 14        bioequivalence standard;15        (4) it is adequately labeled; and16        (5) it is manufactured in compliance with Current Good 17    Manufacturing Practice regulations adopted by the United 18    States Food and Drug Administration.19    (b) An individual or group policy of accident and health 20insurance amended, delivered, issued, or renewed in this State 21on or after January 1, 2024 shall provide coverage for all 22abortifacients, hormonal therapy medication, human 23immunodeficiency virus pre-exposure prophylaxis, and 24post-exposure prophylaxis drugs approved by the United States 25Food and Drug Administration, and follow-up services related 26to that coverage, including, but not limited to, management of   HB2584 Engrossed- 3 -LRB104 08321 BAB 18372 b1side effects, medication self-management or adherence 2counseling, risk reduction strategies, and mental health 3counseling. This coverage shall include drugs approved by the 4United States Food and Drug Administration that are prescribed 5or ordered for off-label use for the purposes described in 6this Section. On or after the effective date of this 7amendatory Act of the 104th General Assembly, this coverage 8shall include pre-PrEP HIV screening, sexually transmitted 9infection screening, kidney function analysis, routine 10laboratory testing, and routine provider visits. 11    (c) The coverage required under subsection (b) is subject 12to the following conditions:13        (1) If the United States Food and Drug Administration 14    has approved one or more therapeutic equivalent versions 15    of an abortifacient drug, a policy is not required to 16    include all such therapeutic equivalent versions in its 17    formulary so long as at least one is included and covered 18    without cost sharing and in accordance with this Section.19        (2) If an individual's attending provider recommends a 20    particular drug approved by the United States Food and 21    Drug Administration based on a determination of medical 22    necessity with respect to that individual, the plan or 23    issuer must defer to the determination of the attending 24    provider and must cover that service or item without cost 25    sharing.26        (3) If a drug is not covered, plans and issuers must   HB2584 Engrossed- 4 -LRB104 08321 BAB 18372 b1    have an easily accessible, transparent, and sufficiently 2    expedient process that is not unduly burdensome on the 3    individual or a provider or other individual acting as a 4    patient's authorized representative to ensure coverage 5    without cost sharing.6    The conditions listed under this subsection (c) also apply 7to drugs prescribed for off-label use as abortifacients. 8    (d) Except as otherwise provided in this Section, a policy 9subject to this Section shall not impose a deductible, 10coinsurance, copayment, or any other cost-sharing requirement 11on the coverage provided. The provisions of this subsection do 12not apply to coverage of procedures to the extent such 13coverage would disqualify a high-deductible health plan from 14eligibility for a health savings account pursuant to the 15federal Internal Revenue Code, 26 U.S.C. 223.16    (e) Except as otherwise authorized under this Section, a 17policy shall not impose any restrictions or delays on the 18coverage required under this Section.19    (f) The coverage requirements in this Section for 20abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 21apply to a multistate plan that does not provide coverage for 22abortion.23    (g) If the Department concludes that enforcement of any 24coverage requirement of this Section for abortifacients may 25adversely affect the allocation of federal funds to this 26State, the Department may grant an exemption to that   HB2584 Engrossed- 5 -LRB104 08321 BAB 18372 b1requirement, but only to the minimum extent necessary to 2ensure the continued receipt of federal funds.3(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 4    Section 10. The Prior Authorization Reform Act is amended 5by adding Section 52 as follows: 6    (215 ILCS 200/52 new)7    Sec. 52. Prior authorization for certain prescription 8drugs; prohibited. A health insurance issuer may not require 9prior authorization for the following prescription drug types 10and their therapeutic equivalents approved by the United 11States Food and Drug Administration: human immunodeficiency 12virus pre-exposure prophylaxis and post-exposure prophylaxis 13medication or human immunodeficiency virus treatment 14medication. 15    Section 99. Effective date. This Act takes effect January 161, 2027.


================================================================================

Raw Text:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly HB2584 EngrossedLRB104 08321 BAB 18372 b1    AN ACT concerning regulation. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Insurance Code is amended by 5changing Section 356z.60 as follows: 6    (215 ILCS 5/356z.60)7    Sec. 356z.60. Coverage for abortifacients, hormonal 8therapy, and human immunodeficiency virus pre-exposure 9prophylaxis and post-exposure prophylaxis.10    (a) As used in this Section:11    "Abortifacients" means any medication administered to 12terminate a pregnancy as prescribed or ordered by a health 13care professional.14    "Health care professional" means a physician licensed to 15practice medicine in all of its branches, licensed advanced 16practice registered nurse, or physician assistant.17    "Hormonal therapy medication" means hormonal treatment 18administered to treat gender dysphoria.19    "Therapeutic equivalent version" means drugs, devices, or 20products that can be expected to have the same clinical effect 21and safety profile when administered to patients under the 22conditions specified in the labeling and that satisfy the 23following general criteria:  HB2584 Engrossed- 2 -LRB104 08321 BAB 18372 b1        (1) it is approved as safe and effective;2        (2) it is a pharmaceutical equivalent in that it:3            (A) contains identical amounts of the same active 4        drug ingredient in the same dosage form and route of 5        administration; and6            (B) meets compendial or other applicable standards 7        of strength, quality, purity, and identity;8        (3) it is bioequivalent in that:9            (A) it does not present a known or potential 10        bioequivalence problem and it meets an acceptable in 11        vitro standard; or12            (B) if it does present such a known or potential 13        problem, it is shown to meet an appropriate 14        bioequivalence standard;15        (4) it is adequately labeled; and16        (5) it is manufactured in compliance with Current Good 17    Manufacturing Practice regulations adopted by the United 18    States Food and Drug Administration.19    (b) An individual or group policy of accident and health 20insurance amended, delivered, issued, or renewed in this State 21on or after January 1, 2024 shall provide coverage for all 22abortifacients, hormonal therapy medication, human 23immunodeficiency virus pre-exposure prophylaxis, and 24post-exposure prophylaxis drugs approved by the United States 25Food and Drug Administration, and follow-up services related 26to that coverage, including, but not limited to, management of   HB2584 Engrossed- 3 -LRB104 08321 BAB 18372 b1side effects, medication self-management or adherence 2counseling, risk reduction strategies, and mental health 3counseling. This coverage shall include drugs approved by the 4United States Food and Drug Administration that are prescribed 5or ordered for off-label use for the purposes described in 6this Section. On or after the effective date of this 7amendatory Act of the 104th General Assembly, this coverage 8shall include pre-PrEP HIV screening, sexually transmitted 9infection screening, kidney function analysis, routine 10laboratory testing, and routine provider visits. 11    (c) The coverage required under subsection (b) is subject 12to the following conditions:13        (1) If the United States Food and Drug Administration 14    has approved one or more therapeutic equivalent versions 15    of an abortifacient drug, a policy is not required to 16    include all such therapeutic equivalent versions in its 17    formulary so long as at least one is included and covered 18    without cost sharing and in accordance with this Section.19        (2) If an individual's attending provider recommends a 20    particular drug approved by the United States Food and 21    Drug Administration based on a determination of medical 22    necessity with respect to that individual, the plan or 23    issuer must defer to the determination of the attending 24    provider and must cover that service or item without cost 25    sharing.26        (3) If a drug is not covered, plans and issuers must   HB2584 Engrossed- 4 -LRB104 08321 BAB 18372 b1    have an easily accessible, transparent, and sufficiently 2    expedient process that is not unduly burdensome on the 3    individual or a provider or other individual acting as a 4    patient's authorized representative to ensure coverage 5    without cost sharing.6    The conditions listed under this subsection (c) also apply 7to drugs prescribed for off-label use as abortifacients. 8    (d) Except as otherwise provided in this Section, a policy 9subject to this Section shall not impose a deductible, 10coinsurance, copayment, or any other cost-sharing requirement 11on the coverage provided. The provisions of this subsection do 12not apply to coverage of procedures to the extent such 13coverage would disqualify a high-deductible health plan from 14eligibility for a health savings account pursuant to the 15federal Internal Revenue Code, 26 U.S.C. 223.16    (e) Except as otherwise authorized under this Section, a 17policy shall not impose any restrictions or delays on the 18coverage required under this Section.19    (f) The coverage requirements in this Section for 20abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 21apply to a multistate plan that does not provide coverage for 22abortion.23    (g) If the Department concludes that enforcement of any 24coverage requirement of this Section for abortifacients may 25adversely affect the allocation of federal funds to this 26State, the Department may grant an exemption to that   HB2584 Engrossed- 5 -LRB104 08321 BAB 18372 b1requirement, but only to the minimum extent necessary to 2ensure the continued receipt of federal funds.3(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 4    Section 10. The Prior Authorization Reform Act is amended 5by adding Section 52 as follows: 6    (215 ILCS 200/52 new)7    Sec. 52. Prior authorization for certain prescription 8drugs; prohibited. A health insurance issuer may not require 9prior authorization for the following prescription drug types 10and their therapeutic equivalents approved by the United 11States Food and Drug Administration: human immunodeficiency 12virus pre-exposure prophylaxis and post-exposure prophylaxis 13medication or human immunodeficiency virus treatment 14medication. 15    Section 99. Effective date. This Act takes effect January 161, 2027.